Adding immunotherapy to chemo may boost pCR and downstaging rates in the neoadjuvant setting for muscle-invasive bladder ...

Panelists discuss how balancing effective disease control with managing treatment-related adverse effects in patients with chronic myeloid leukemia (CML) requires a strategic approach that may ...

Panelists discuss the EMERALD trial data, which shows the effectiveness of elacestrant in patients with estrogen receptor 1 (ESR1) mutations, particularly those who were on first-line CDK 4/6 ...

Panelists discuss the safety profile and adverse effects of elacestrant, highlighting its relatively mild nausea and ease of administration compared with other endocrine therapies.